Cormorant Asset Management’s Damora Therapeutics DMRA Stock Holding History

Cormorant Asset Management’s Portfolio DMRA Stock Details DMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26M	Sell	1,000,000 -525,000	-34%	-$12.7M	1.33%	23
2026 Q1	$39.5M	Buy	+1,525,000	New	+$39.2M	1.98%	16
2023 Q3	–	Sell	-40,810	Closed	-$2.57M	–	59
2023 Q2	$2.57M	Hold	40,810	–	–	0.14%	58
2023 Q1	$2.03M	Hold	40,810	–	–	0.13%	60
2022 Q4	$1.17M	Hold	40,810	–	–	0.08%	63
2022 Q3	$1.93M	Hold	40,810	–	–	0.13%	62
2022 Q2	$1.76M	Hold	40,810	–	–	0.13%	63
2022 Q1	$2.25M	Hold	40,810	–	–	0.17%	63
2021 Q4	$3.09M	Sell	40,810 -5,219	-11%	-$410K	0.18%	65
2021 Q3	$4.13M	Sell	46,029 -24,125	-34%	-$2.58M	0.17%	74
2021 Q2	$8.87M	Sell	70,154 -15,875	-18%	-$2.16M	0.3%	67
2021 Q1	$13.1M	Hold	86,029	–	–	0.29%	65
2020 Q4	$26.5M	Buy	+86,029	New	+$32M	0.63%	39

Other funds holding DMRA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Jupiter Topco New York $245B AUM

RCP

Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Cormorant Asset Management's DMRA Position: Q2 2026 in Review

Cormorant Asset Management reduced its Damora Therapeutics (DMRA) stake by 34% in Q2 2026, selling an estimated $12.7M and leaving 1,000,000 shares worth $26M. The position accounts for 1.33% of the portfolio, ranked #23.

Cormorant Asset Management first reported a position in DMRA in Q4 2020 and has held it in 13 quarters since. The position peaked at $39.5M in Q1 2026. 104 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

Cormorant Asset Management held 1,000,000 shares of Damora Therapeutics worth $26M as of Q2 2026.
Cormorant Asset Management sold 525,000 Damora Therapeutics shares in Q2 2026, an estimated $12.7M.
Damora Therapeutics made up 1.33% of Cormorant Asset Management's portfolio in Q2 2026, its #23 holding.
Cormorant Asset Management first reported a position in Damora Therapeutics in Q4 2020 and has held it in 13 quarters since.
Cormorant Asset Management's Damora Therapeutics position peaked at $39.5M in Q1 2026.
104 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on Cormorant Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.